What is DermTech?
DermTech, Inc. operates at the intersection of biotechnology and clinical dermatology, specializing in the development and commercialization of non-invasive genomics tests. The company's core value proposition lies in its ability to provide molecular-level insights into skin health without the need for traditional, invasive biopsy procedures. By focusing on melanoma diagnosis, DermTech addresses a critical gap in the oncology market, offering a scalable solution that improves diagnostic accuracy and patient outcomes. The firm's market position is bolstered by its commitment to rigorous clinical validation and the integration of its diagnostic tools into standard dermatological workflows, effectively bridging the gap between advanced genomic research and routine clinical practice.
How much funding has DermTech raised?
DermTech has raised a total of $87.4M across 4 funding rounds:
Other Financing Round
$10M
Other Financing Round
$2.4M
Series C
$10M
Share Placement
$65M
Other Financing Round (2007): $10M with participation from Gary Jacobs and Gene Salkind
Other Financing Round (2015): $2.4M led by Undisclosed
Series C (2017): $10M supported by RTW Investments
Share Placement (2020): $65M featuring Undisclosed
Key Investors in DermTech
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
Gary Jacobs
An individual investor with a history of supporting early-stage medical technology and diagnostic ventures.
Gene Salkind
A private investor focused on backing innovative healthcare solutions and molecular diagnostic platforms.
What's next for DermTech?
Looking ahead, the recent capital infusion is expected to catalyze DermTech's operational expansion and research initiatives. The company is likely to prioritize the scaling of its laboratory infrastructure to meet increasing demand for its diagnostic services while simultaneously investing in the development of new genomic markers for broader dermatological applications. As the firm transitions into a more mature phase of its lifecycle, strategic focus will likely shift toward enhancing market penetration and securing broader insurance coverage for its tests. By maintaining its commitment to innovation and clinical excellence, DermTech is poised to remain a key player in the evolving landscape of precision medicine, potentially setting new benchmarks for non-invasive diagnostic standards in the oncology space.
See full DermTech company page
